Eclampsia

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

Retrieved on: 
Wednesday, March 6, 2024

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
  • The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (“PLGF”) in maternal plasma specimens.
  • With the Triage PLGF test, clinicians can be positioned to better detect angiogenic imbalance and assess the risk for these complications.
  • The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument.

NIH grants $2.3M to evaluate the impact of ViTrack® on maternal and child health during pregnancy

Retrieved on: 
Tuesday, February 20, 2024

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Dynocardia, developer of ViTrack, the first-of-its-kind non-invasive, wearable blood pressure (BP) and heart monitor, and NYC Health + Hospitals, the nation's largest safety net health system, are partnering on a study of hypertensive diseases of pregnancy (HDP). The study will include at least 150 women who are pregnant or have recently given birth. The perinatal study addresses a long-standing unmet need for accurate and continuous BP for reliable diagnosis of HDP and for prediction and early detection of preeclampsia. The research is being funded by a $2.3M grant from the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI).

Key Points: 
  • The research is being funded by a $2.3M grant from the National Institute of Health's National Heart, Lung, and Blood Institute (NHLBI).
  • HDP, a constellation of high BP disorders that may occur during pregnancy, affects both the mother and the child and is a leading cause of pregnancy-related complications and death globally.
  • While the risks posed by HDP have doubled over the past decade in the United States, the effects on the maternal population are not evenly distributed.
  • Moreover, pregnant women are even more vulnerable to these errors due to hemodynamic and vascular changes that occur during pregnancy.

REST Technologies INC breakthrough technologies help monitor pregnant women for dangerous sleep disorders.

Retrieved on: 
Friday, September 8, 2023

HOUSTON, Sept. 8, 2023 /PRNewswire-PRWeb/ -- The National Institute of Health (NIH) awards REST Technologies, Inc. (REST), a Small Business Innovation Research (SBIR) grant to demonstrate the ability to monitor sleep in pregnant women nightly, to identify the onset of obstructive sleep apnea (OSA), which could improve outcomes in high-risk obstetric patients. This is done by using the REST Tracker platform, developed by REST Technologies, Inc., that incorporates home sleep testing technology, developed by SleepImage which obtains data from a ring when asleep.

Key Points: 
  • HOUSTON, Sept. 8, 2023 /PRNewswire-PRWeb/ -- The National Institute of Health (NIH) awards REST Technologies, Inc. (REST) , a Small Business Innovation Research (SBIR) grant to demonstrate the ability to monitor sleep in pregnant women nightly, to identify the onset of obstructive sleep apnea (OSA), which could improve outcomes in high-risk obstetric patients.
  • This is done by using the REST Tracker platform , developed by REST Technologies, Inc .
  • REST Technologies, Inc.'s founding CEO, Jerald Simmons, MD appreciated the need to capture the sleep data and its important clinical value.
  • Now RPM wearable devices can be easily accessed by physicians, medical groups and industries with the REST Tracker by REST Technologies, to manage their users, assisting the outcomes for better sleep.

This is Our Lane - Too: Joint Statement on the Maternal Health Crisis from the Association of Black Cardiologists, American College of Cardiology and American Heart Association

Retrieved on: 
Wednesday, May 17, 2023

Urgent action is needed to combat the maternal morbidity and mortality crisis in America and cardiologists have a vital role to play.

Key Points: 
  • Urgent action is needed to combat the maternal morbidity and mortality crisis in America and cardiologists have a vital role to play.
  • Urgent action is needed to combat the maternal health crisis in America and cardiologists have a vital role to play.
  • The ABC also launched the " We Are the Faces of Black Maternal Health™ " campaign in 2021 to tell the stories of the maternal health crisis faced by cardiologists along with their patients.
  • We encourage all cardiovascular specialists to double down on their efforts to reduce maternal mortality and to eliminate racial and ethnic gaps in maternal health outcomes.

Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce Launch of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers by Their Partner Athenex Pharmaceutical Division (APD)

Retrieved on: 
Monday, March 20, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230320005186/en/
    Alter Pharma #MakingAffordableMedicinesAvailableToAll Every day we ensure equal access to medicines and continuity of treatment for patients.
  • (Graphic: Business Wire)
    Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia.
  • This latest launch of Magnesium Sulfate Injection will help reduce the recent supply issues for the product experienced in the U.S.
  • This achievement marks the second ANDA commercialization for Milla Pharmaceuticals Inc. and the third for an Alter Pharma Group product in the U.S. market.

First Ever “Future of Pregnancy Health” Report Reveals 9 out of 10 New or Expecting Moms Want More Information About Their Individual Risk of Pregnancy Complications to Optimize Prevention

Retrieved on: 
Tuesday, November 8, 2022

Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever Future of Pregnancy Health Report .

Key Points: 
  • Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever Future of Pregnancy Health Report .
  • The results spotlight an urgent need to identify who is most at risk of complications and tailor education and preventive care toward them.
  • The study also found new or expecting moms overwhelmingly believe knowing their risk of pregnancy complications can enable proactive, personalized and preventive pregnancy care.
  • This new approach to pregnancy health is desperately needed to chart a new course for moms in the United States.

Morgan Stanley and Centri Tech Foundation Announce Inaugural Winners of the Social Justice Innovation Awards

Retrieved on: 
Thursday, September 29, 2022

Morgan Stanley, in partnership with Centri Tech Foundation, today announced the inaugural winners of the Social Justice Innovation Awards .

Key Points: 
  • Morgan Stanley, in partnership with Centri Tech Foundation, today announced the inaugural winners of the Social Justice Innovation Awards .
  • We are excited to announce the inaugural Social Justice Innovation Award winners, said Rey Ramsey, Chairman of Centri Tech Foundation.
  • Each winner of the Social Justice Innovation Awards was selected for developing a breakthrough concept aimed at solving critical social justice challenges.
  • Centri Tech Foundation is proud to support the winners of the Social Justice Innovation Awards with the resources and opportunities needed to effect transformative change, said Marta Urquilla, President of Centri Tech Foundation.

Worldwide Blood Transfusion Devices Industry to 2026 - by Product, Blood Component, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021

The global blood transfusion devices market is segmented based on product, type, blood component, end user, company, and region.

Key Points: 
  • The global blood transfusion devices market is segmented based on product, type, blood component, end user, company, and region.
  • To estimate and forecast the market size of global blood transfusion devices market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global blood transfusion devices market based on product, blood component, end user, company and regional distribution.
  • To identify key sustainable strategies adopted by market players in global blood transfusion devices market.

B. Braun Announces Nationwide Availability of Magnesium Sulfate Family of Products

Retrieved on: 
Wednesday, December 8, 2021

Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it."

Key Points: 
  • Our reliable supply of Magnesium Sulfate products will support providers by ensuring availability when their patients need it."
  • Someof the many characteristics of B. Braun's Magnesium Sulfate products include:
    Domestically manufactured and sourced: In addition to being manufactured in Irvine, California, B. Braun's Magnesium Sulfate products are produced with American-made active pharmaceutical ingredients, helping ensure consistent supply levels.
  • Eco-friendly Packaging: B. Braun's Magnesium Sulfate products do not require an overwrap like other ready-to-use Magnesium Sulfate pre-mixed bags, reducing landfill waste.
  • Ready-to-Use Pre-Mixed Bags: Doses include Magnesium Sulfate in 5% Dextrose, 1 g/100 mL, Magnesium Sulfate in Water, 2 g/50 mL, Magnesium Sulfate in Water, 4 g/50 mL, and Magnesium Sulfate in Water, 4 g/100 mL.

Milla Pharmaceuticals Inc. Announces Approval of a Generic Version of Magnesium Sulfate in Water for Injection, in Non-PVC, Single-Patient Use Containers

Retrieved on: 
Tuesday, November 9, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211109005804/en/
    Magnesium Sulfate Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively.
  • Magnesium Sulfate Injection is currently on the ASHP drug shortage list of essential medications.
  • This approval and near-term launch of Magnesium Sulfate Injection will help to reduce supply issues experienced in the US.
  • Magnesium Sulfate Injection is another example of a product in shortage in the US market for which we can offer a high-quality generic equivalent to the patients in need.